8XBK
Crystal Structure of Human Liver Fructose-1,6-bisphosphatase Complexed with a Covalent Inhibitor
8XBK の概要
エントリーDOI | 10.2210/pdb8xbk/pdb |
分子名称 | Fructose-1,6-bisphosphatase 1, N-[2-[4-[(3-bromophenyl)carbamoylsulfamoyl]phenyl]ethyl]ethanamide, 1,2-ETHANEDIOL, ... (5 entities in total) |
機能のキーワード | covalent inhibitor, protein binding |
由来する生物種 | Homo sapiens (human) |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 155778.78 |
構造登録者 | |
主引用文献 | Cao, H.,Huang, Z.,Liu, Z.,Zhang, X.,Ren, Y.,Hameed, M.S.,Rao, L.,Makunga, N.P.,Dobrikov, G.M.,Wan, J. Structure-Guided Design of Affinity/Covalent-Bond Dual-Driven Inhibitors Targeting the AMP Site of FBPase. J.Med.Chem., 67:20421-20437, 2024 Cited by PubMed Abstract: Fructose-1,6-bisphosphatase (FBPase) has attracted substantial interest as a target associated with cancer and type II diabetes. FBPase inhibitors targeting the AMP allosteric site have been documented, but their limited selectivity has raised concerns about adverse effects. To address this issue, we designed the affinity/covalent-bond dual-driven inhibitors based on the pharmacophore knowledge of the AMP pocket and neighboring cysteine residue (C179) of FBPase using the cysteine-targeting reactivity warhead screen followed by a structural optimization strategy. Pull-down and Western Blotting assays confirmed FBPase as a direct target in hepatic cells. X-ray cocrystallographic structure of FBPase- and Cov_DOX calculation demonstrated that hydrogen bonding and π-π stacking were the predominant driving force for the inhibition of sulfonylurea-based FBPase covalent inhibitors, while covalent binding with C179 enhances the inhibitors' long-lasting hypoglycemic effects. Together, this work highlights the potential of affinity/covalent-bond dual-driven inhibitors in drug development and provides a promising approach for developing potent drugs targeting AMP-associated proteins. PubMed: 39520680DOI: 10.1021/acs.jmedchem.4c01886 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.42 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
